ArticleACG case reports journal2026
Deep Durable Response in Metastatic Hepatocellular Carcinoma After Early Discontinuation of Atezolizumab-Bevacizumab.
Article in ACG case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced stage hepatocellular carcinoma with metastatic disease is typically managed with combination systemic therapy. Objective responses generally require several months of treatment. We present a patient with metastatic hepatocellular carcinoma who received 4 cycles of atezolizumab and bevacizumab before treatment cessation due to grade 2 immune-related adverse events. Despite early discontinuation, the patient demonstrated progressive reduction in intrahepatic and extrahepatic tumor burden with normalization of alpha-fetoprotein and durable disease control for 19 months off therapy. This case highlights the potential for sustained antitumor activity following brief exposure to immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.